Literature DB >> 26894110

A Rare Presentation of Lupus Nephritis Flare up with Posterior Reversible Leucoencephalopathy.

S Hima Mani1, S M Shivaprasad2, L Umesh3.   

Abstract

Systemic lupus erythematosus (SLE) is associated with various neurologic or psychiatric abnormalities and Posterior Reversible Leuco Encephalopathy Syndrome (PRES) is very rare neurological manifestation in SLE. PRES is associated with various clinical manifestations, like, seizures, visual loss, headaches, vomiting altered mental status and rarely focal neurological deficits. Other predisposing condition associated with PRES is eclampsia, accelerated hypertension, uraemia, transplantation, autoimmune diseases and/or use of immunosuppressive drugs. It is important to recognise PRES since it is a potentially reversible. We describe an unusual case of PRES caused by uraemia during lupus flare up in a patient with biopsy proven class IV lupus nephritis who presented with features of asymmetrical quadriparesis which completely reversed after haemodialysis sessions and treating lupus flare up. In our case she presented with quadriparesis which is a rare presentation and hypertensive encephalopathy was not present.

Entities:  

Keywords:  (HBP) High Blood Pressure; NIH (National Institute of Health); SLE- Systemic Lupus Nephritis

Year:  2016        PMID: 26894110      PMCID: PMC4740638          DOI: 10.7860/JCDR/2016/14770.7038

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  13 in total

Review 1.  Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed.

Authors:  V L Stott; M A Hurrell; T J Anderson
Journal:  Intern Med J       Date:  2005-02       Impact factor: 2.048

Review 2.  Posterior reversible encephalopathy syndrome in systemic lupus erythematosus.

Authors:  Khalil El Karoui; Moglie Le Quintrec; Eric Dekeyser; Aude Servais; Aurélie Hummel; Fouad Fadel; Fadi Fakhouri
Journal:  Nephrol Dial Transplant       Date:  2007-12-01       Impact factor: 5.992

3.  Hemodynamic and permeability changes in posterior reversible encephalopathy syndrome measured by dynamic susceptibility perfusion-weighted MR imaging.

Authors:  Lauren M Brubaker; J Keith Smith; Yueh Z Lee; Weili Lin; Mauricio Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

4.  Erythropoietin-associated hypertensive posterior leukoencephalopathy.

Authors:  N Delanty; C Vaughan; S Frucht; P Stubgen
Journal:  Neurology       Date:  1997-09       Impact factor: 9.910

5.  Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.

Authors:  Ki Chul Shin; Hyo Jin Choi; Yeong Deok Bae; Jung Chan Lee; Eun Bong Lee; Yeong Wook Song
Journal:  J Clin Rheumatol       Date:  2005-06       Impact factor: 3.517

Review 6.  Posterior reversible encephalopathy syndrome--an underrecognized manifestation of systemic lupus erythematosus.

Authors:  Jason K Kur; John M Esdaile
Journal:  J Rheumatol       Date:  2006-09-01       Impact factor: 4.666

7.  Posterior reversible encephalopathy syndrome due to severe hypercalcemia.

Authors:  O Kastrup; M Maschke; I Wanke; H C Diener
Journal:  J Neurol       Date:  2002-11       Impact factor: 4.849

8.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

9.  Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images.

Authors:  Diego J Covarrubias; Patrick H Luetmer; Norbert G Campeau
Journal:  AJNR Am J Neuroradiol       Date:  2002 Jun-Jul       Impact factor: 3.825

10.  Posterior reversible encephalopathy syndrome (PRES) in critically ill obstetric patients.

Authors:  Giuseppe Servillo; Pasquale Striano; Salvatore Striano; Fabio Tortora; Patrizia Boccella; Edoardo De Robertis; Flavia Rossano; Francesco Briganti; Rosalba Tufano
Journal:  Intensive Care Med       Date:  2003-08-06       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.